Example: Heart Attack
Clinical Trials on Uveal Diseases
Total 0 results
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Medical Conditions
- COVID-19
- Candida Vulvovaginitis
- Detectable Prostate Nodules
- Emergence of Bacterial Resistance to Antibiotics
- Follicular Lymphoma Grade 3A
- Legumes Allergy
- Metastatic Microsatellite-stable Colorectal Cancer
- Neuromuscular Diseases in Children
- Obesity and Type 2 Diabetes
- Ovarian Serous Cystadenocarcinoma
- Relapsed Acute Erythroid Leukemia
- Skin Graft (Allograft) (Autograft) Failure
- Thyroid Related Eye Disease
- Thyroid Surgery for Benign Disease
- View Full List
Sponsors and Collaborators
- Bruyere Academic Medical Organization
- Clinica Universidad de Navarra, Universidad de Navarra
- Davide La Regina
- Dongguan Shi People's Hospital
- Dr. Markus Ziesmann
- National Research Center for Hematology, Russia
- Obalon Therapeutics, Inc.
- Samaritan Health Services
- Sapporo Higashi Tokushukai Hospital
- Shahid Beheshti University
- Travis Callahan
- University Hospital, Catania
- Utah State University
- View Full List
Drug Interventions
- 1. amyloid PET；2. T807 PET
- Artesunate plus Amodiaquine
- BLI1100 - modified formulation
- Botulinum Toxins
- CCT3833
- Furosemide dose escalation
- Haemostatic solution "Haemoblock" application
- Injection of TVEC into target lesions - week 1-2
- Menthol flavor
- OXY 50 mg
- Placebo (Part A)
- Sildenafil 80 mg
- urea/lactic acid
- View Full List
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations